Cardiovascular Disease Management

Introduction to Ezetimibe Therapy

Ezetimibe monotherapy is generally well-tolerated, with a side effect profile similar to placebo in most clinical trials, and when combined with statins, it provides additional LDL-cholesterol lowering without substantially increasing adverse effects, as noted by the American College of Cardiology 1

Elevated liver enzymes may occur, particularly when ezetimibe is combined with statins, and the American College of Cardiology recommends baseline liver function tests and regular monitoring, especially with concomitant statin therapy 1
Ezetimibe appears to be generally safe and well-tolerated in pediatric populations with familial hypercholesterolemia, according to the American Heart Association 2
Common adverse effects of ezetimibe monotherapy include upper respiratory tract infection, diarrhea, arthralgia, sinusitis, extremity pain, flu-like symptoms, and fatigue 3, 1
When combined with statins, ezetimibe may cause nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, extremity pain, back pain, and fatigue 3, 1

Patients with moderate to severe hepatic disease should avoid ezetimibe, and caution is advised in moderate to severe renal impairment, with no dosage adjustment needed in mild renal insufficiency, as recommended by the American College of Cardiology 1
Elderly patients are at increased risk of volume depletion with dapagliflozin, but ezetimibe appears safe without dosage adjustments, according to the American Geriatrics Society 4
Ezetimibe appears safe in older patients, with no specific dosage adjustments needed based on age, according to the American Heart Association 5, 1
Ezetimibe is safe and well-tolerated in pediatric populations 2
No safety data is available for pregnancy and lactation; avoid use, as stated by the American College of Obstetricians and Gynecologists 1, 6

Regular monitoring of liver function and lipid profiles is advised to assess efficacy and safety, and patients should be instructed to report muscle symptoms promptly, as recommended by the American College of Cardiology 1, 2
Baseline liver function tests are recommended before initiating ezetimibe therapy, and should be monitored during treatment, especially with concomitant statin therapy 5, 1
Regular lipid profile monitoring is recommended to assess efficacy 7, 1
Regular monitoring of eGFR is recommended, particularly with dapagliflozin, as stated by the American Diabetes Association 8, 4
Monitoring for signs of volume depletion, including hypotension, is necessary, especially in elderly patients or those on diuretics, according to the American Heart Association 8, 4

Cyclosporine may increase ezetimibe levels, and fibrates may increase the bioavailability of ezetimibe 3, 5, 1
Bile acid sequestrants should be taken at least 2 hours before or 4 hours after ezetimibe 3, 5, 1
Statins may increase the risk of myopathy and hepatic effects when used with ezetimibe, but are generally safe in combination 7, 1
Ezetimibe can be safely used with tadalafil, as there are no significant drug interactions documented between these medications 1

The combination of ezetimibe, rosuvastatin, and dapagliflozin can cause several important side effects, including genital mycotic infections, volume depletion, diabetic ketoacidosis, liver enzyme elevations, myopathy, and gastrointestinal disturbances, requiring careful monitoring and management, as recommended by the American Diabetes Association and the American Heart Association 8, 4
Dapagliflozin carries several important potential adverse effects, including genital mycotic infections, which can be mitigated with proper genital hygiene, according to the American College of Cardiology 4
The risk of diabetic ketoacidosis (DKA) is higher in patients with insulin deficiency, though rare in Type 2 diabetes, and requires prompt discontinuation, evaluation, and treatment if suspected, as stated by the European Association for the Study of Diabetes 8
Dapagliflozin may cause volume depletion and hypotension, particularly concerning when ill or fasting, and necrotizing fasciitis of the perineum (Fournier gangrene) is a rare but serious complication, as reported by the American Heart Association 8, 4
Dapagliflozin is contraindicated with eGFR <30 mL/min/1.73m², and the glucose-lowering effect is minimal at eGFR <45 mL/min/1.73m², according to the National Kidney Foundation 8, 4